Replies to post #300127 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

who wrote this article, Stupp?? If yes, how could we get a fair one from such competitors?

[Sojourner55]

Anders, I'm saying that the two citations (7 and 14) she used to support her claim about patient selection bias does not have anything in the articles to support that claim.

She is not referring to the link you posted. Alexander thought it was but nothing in that quote points to it.

While the interim analysis from the trial showed an eight-month OS survival benefit for the addition of DCVax-L to SoC, key stakeholders in the field have indicated potential patient selection bias (7,14)

[photonic5]

We really need to put this to bed.

The nature of how DCVAX works makes screening appear problematic, but it’s not really the case. Because the patient is screened PRE surgery in this trial (and before tissue pathology), there is a great chance for exclusion due to pathology indicating the tumor is not GBM. Tumors are only identified through pathology (poat surgery, as is the case with brain tumors). Radiology cannot diagnose tumor tissue. Other GBM trials that can screen POST surgery (and after pathology) don’t have this burden, so they don’t have to screen as many patients. It is solely the nature of the vaccine that requires pre-surgical screening. Patients weren’t eligible for this trial without surgery and a reasonable resection.

While a critic or competitor will find ANY reason to downplay the competition, it should be noted that there is a very good explanation for why our screening numbers are higher in comparison to post surgical/pathology screened trials in GBM.